APA (7th ed.) Citation

B, S., E, C., C, W., E, Y., R, B., C, B., . . . EA, H. (2024). Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. EJHaem, 5(2), 325. https://doi.org/10.1002/jha2.870

Chicago Style (17th ed.) Citation

B, Shaw, et al. "Poor Outcomes for Trial-ineligible Patients Receiving Polatuzumab for Relapsed/refractory Diffuse Large B-cell Lymphoma in Routine Care: An Australian Lymphoma and Related Diseases Registry Project." EJHaem 5, no. 2 (2024): 325. https://doi.org/10.1002/jha2.870.

MLA (9th ed.) Citation

B, Shaw, et al. "Poor Outcomes for Trial-ineligible Patients Receiving Polatuzumab for Relapsed/refractory Diffuse Large B-cell Lymphoma in Routine Care: An Australian Lymphoma and Related Diseases Registry Project." EJHaem, vol. 5, no. 2, 2024, p. 325, https://doi.org/10.1002/jha2.870.